Return to Clinical Trials Search Results

A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.

Primary Evaluate anti-tumor efficacy of VB10.16 + placebo and VB10.16 + Atezolizumab Secondary Further evaluate anti-tumor efficacy and response durability of VB10.16 + placebo and VB10.16 + atezolizumab Evaluate clinical efficacy of VB10.16 + placebo and VB10.16 + atezolizumab Characterize safety of VB10.16 + placebo and VB10.16 + atezolizumab Exploratory Assess biomarkers related to clinical response of VB10.16 + placebo and VB10.16 + atezolizumab

Primary Evaluate anti-tumor efficacy of VB10.16 + placebo and VB10.16 + Atezolizumab Secondary Further evaluate anti-tumor efficacy and response durability of VB10.16 + placebo and VB10.16 + atezolizumab Evaluate clinical efficacy of VB10.16 + placebo and VB10.16 + atezolizumab Characterize safety of VB10.16 + placebo and VB10.16 + atezolizumab Exploratory Assess biomarkers related to clinical response of VB10.16 + placebo and VB10.16 + atezolizumab